Anthony Cerami | |
|---|---|
 | |
| Born | October 3, 1940 (age 84) Newark, New Jersey |
| Nationality | American |
| Education | Rockefeller University, Rutgers University |
| Known for | Medical Research |
| Awards | Paul Ehrlich and Ludwig Darmstaedter Prize (2018) |
Anthony Cerami (born October 3, 1940 [1] ) is an American entrepreneur and medical research scientist.
Anthony Cerami received his undergraduate degree from Rutgers University and received a Ph.D. in 1967 from Rockefeller University, New York, completed postdoctoral fellowships at Harvard Medical School and at the Jackson Laboratory and served for 20 years as Professor and Head of the Laboratory of Medical Biochemistry, and Dean of Graduate and Postgraduate Studies at Rockefeller. [2] [3]
In late 1986 Cerami was a founder of Alteon, Inc. [4] which licensed patents filed by Rockefeller on work Cerami had done there; Cerami took a seat on the board of the company, was on the scientific advisory board, and received research funding from Alteon first at Rockefeller and then at Picower, [5] and later through his consulting company and the "Kenneth S. Warren Laboratories, Inc." [6] In the spring of 1999 Alteon and Cerami terminated the consulting agreement and research agreement with Warren Labs, and Cerami resigned from the board. [7]
Cerami was one of 15 Rockefeller faculty who vocally opposed the appointment of David Baltimore as president of Rockefeller in 1989. [8] Due in part to that disagreement, in 1991 Cerami left Rockefeller to found (with Jeffry Picower) the Picower Institute for Medical Research on the grounds of North Shore University Hospital. [8] [9] As of March 1998, Cerami was President of Cerami Consulting and was president and Trustee of the "Kenneth S. Warren Laboratories, Inc. [10] The Picower Institute was closed down by Picower in 2001, [11] and early the next year it was acquired by The Institute for Medical Research at North Shore-LIJ. [12]
As of 2001, Cerami was the director and lead researcher of the Kenneth S. Warren Institute, [13] and in 2001, Warren Pharmaceuticals was formed to commercialize inventions made at the institute; Cerami was chairman of the board. [14]
Cerami has led research programs into genetic, metabolic and infectious diseases, with the goal of translating scientific discovery into drugs and diagnostic tests. He received funding from the Rockefeller Foundation to study neglected tropical diseases and traveled to Africa, where he became interested in the wasting, one of the symptoms of African sleeping sickness. [2]
He developed and validated a measurement of glycated hemoglobin to monitor control of blood sugar in people with diabetes, [15] [16] and a paper he published in 1985 using polyclonal antibodies against tumour necrosis factor-alpha was important in the field of immunology for demonstrating that TNF-alpha causes disease and blocking it could be a treatment. [2] [17] [18]
Work that he did while he was at Rockefeller on advanced glycation end-products (AGEs) and protein cross-linking and their roles in metabolic diseases and aging was patented by Rockfeller and licensed to Alteon Inc. in 1987 and in 1992 the company licensed further work that Cerami did on the use of pimagedine to reduce AGEs. [5]
At the Warren institutes, he led work on erythropoietin derivatives that were called "tissue protective cytokines"; this work was licensed to Warren Pharmaceuticals and through them to Lundbeck in 2001; [14] the development program was terminated in 2007. [19]
He is the recipient of the Luft Award in Diabetes [2] and the Frederick Banting Medal for Scientific Achievement, awarded by the American Diabetes Association in recognition of his lifelong work on diabetes.
Glycated hemoglobin is a form of hemoglobin (Hb) that is chemically linked to a sugar. 'Glycosylated haemoglobin' is a misnomer, as glycation and glycosylation are different processes, of which only the former is relevant in this case.
DOV Pharmaceutical was a biotechnology company that focused on therapies primarily for central nervous system conditions. It was founded in 1995 by former employees of American Cyanamid, and in 1998 it in-licensed drugs discovered at American Cyanamid for further development. It held an IPO on NASDQ in 2002, and its shares plunged days later after negative details about a past relationship between Élan and DOV emerged.
Alagebrium was a drug candidate developed by Alteon, Inc. It was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts (AGEs), thereby reversing one of the main mechanisms of aging. Through this effect Alagebrium is designed to reverse the stiffening of blood vessel walls that contributes to hypertension and cardiovascular disease, as well as many other forms of degradation associated with protein crosslinking. Alagebrium has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic heart failure.
A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their treatment. The important side effects of TNF inhibitors include lymphomas, infections, congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.
Jan T. Vilček is a Slovak-American biomedical scientist, educator, inventor and philanthropist. He is a professor in the department of microbiology at the New York University School of Medicine, and chairman and CEO of The Vilcek Foundation. Vilček received his M.D. degree from Comenius University Medical School in Bratislava in 1957; and his Ph.D. in Virology from the Institute of Virology, Czechoslovak Academy of Sciences, Bratislava, in 1962.
North Shore University Hospital is a part of Northwell Health, New York State's largest healthcare provider and private employer. It is one of two primary teaching hospitals for the Zucker School of Medicine, offering residency programs, postgraduate training programs and clinical fellowships. It is located in Manhasset, New York, in Nassau County, on Long Island.
CD120 can refer to two members of the tumor necrosis factor receptor superfamily: tumor necrosis factor receptor 1 (TNFR1) and tumor necrosis factor receptor 2 (TNFR2).
Bruce Alan Beutler is an American immunologist and geneticist. Together with Jules A. Hoffmann, he received one-half of the 2011 Nobel Prize in Physiology or Medicine, for "discoveries concerning the activation of innate immunity." Beutler discovered the long-elusive receptor for lipopolysaccharide. He did so by identifying spontaneous mutations in the gene coding for mouse Toll-like receptor 4 (Tlr4) in two unrelated strains of LPS-refractory mice and proving they were responsible for that phenotype. Subsequently, and chiefly through the work of Shizuo Akira, other TLRs were shown to detect signature molecules of most infectious microbes, in each case triggering an innate immune response.
Molecular Medicine is a peer-reviewed open access medical journal published by The Feinstein Institute for Medical Research. It was established in 1994 by the Picower Institute for Medical Research, which had been established in 1991 by Anthony Cerami with funding from Jeffry Picower which eventually was absorbed into Feinstein.
The Feinstein Institutes for Medical Research in Manhasset, Nassau County, New York, United States, on Long Island, constitute the research arm of Northwell Health. Feinstein is home to 50 research labs, 2,500 clinical research studies, and 5,000 professional and support staff. Feinstein scientists conduct research in molecular medicine, genetics, cancer, brain research, mental health, autoimmunity and bioelectronic medicine, among others. Feinstein is the laboratory and faculty home of the Elmezzi Graduate School of Molecular Medicine. Students with an MD degree may earn a PhD in molecular medicine via the Zucker School of Medicine, as part of the medical school's MD/PhD or PhD programs.
Kevin J. Tracey, a neurosurgeon and inventor, is the president and CEO of the Feinstein Institute for Medical Research, professor of neurosurgery and molecular medicine at the Zucker School of Medicine, and president of the Elmezzi Graduate School of Molecular Medicine in Manhasset, New York. The Public Library of Science Magazine, PLOS Biology, recognized Tracey in 2019 as one of the most cited researchers in the world.
Kenneth S. Warren was an American scientist, physician, educator and public health advocate. He was an expert on tropical disease, in particular schistosomiasis.
"Sickle Cell Anemia, a Molecular Disease" is a 1949 scientific paper by Linus Pauling, Harvey A. Itano, Seymour J. Singer and Ibert C. Wells that established sickle-cell anemia as a genetic disease in which affected individuals have a different form of the metalloprotein hemoglobin in their blood. The paper, published in the November 25, 1949 issue of Science, reports a difference in electrophoretic mobility between hemoglobin from healthy individuals and those with sickle-cell anemia, with those with sickle cell trait having a mixture of the two types. The paper suggests that the difference in electrophoretic mobility is probably due to a different number of ionizable amino acid residues in the protein portion of hemoglobin, and that this change in molecular structure is responsible for the sickling process. It also reports the genetic basis for the disease, consistent with the simultaneous genealogical study by James V. Neel: those with sickle-cell anemia are homozygous for the disease gene, while heterozygous individuals exhibit the usually asymptomatic condition of sickle cell trait.
Semapimod (INN), formerly known as CNI-1493, is an investigational new drug which has anti-inflammatory, anti-cytokine, immunomodulatory, antiviral and antimalarial properties.
Pimagedine, also known as aminoguanidine, is an investigational drug for the treatment of diabetic nephropathy that is no longer under development as a drug. Pimagedine functions as an inhibitor of diamine oxidase and nitric oxide synthase. It acts to reduce levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone, glyoxal, methylglyoxal, and related dicarbonyls. These reactive species are converted to less reactive heterocycles by this condensation reaction.
Jeffry M. Picower was an American investor involved in the Madoff investment scandal. He was the largest beneficiary of Madoff's Ponzi scheme, and his widow agreed to have his estate settle the claims against it by Madoff trustee Irving Picard for $7.2 billion, the largest single forfeiture in American judicial history.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 5,400 people. Medpace's mission statement is "to accelerate the global development of safe and effective medical therapeutics" through its high science and disciplined operating approach that leverages local, regulatory, and deep therapeutic expertise across all major areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective. Operating under a full-service model, Medpace provides a therapeutically focused, integrated, global approach to clinical development. The company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Dena Minning Grayson is an American medical doctor and researcher. In 2016, she ran unsuccessfully for the Democratic nomination for the United States House of Representatives for Florida's 9th congressional district.
Neurobiological Technologies, Inc. ("NTI") was a biotechnology company that was founded in 1987 by Enoch Callaway and John B. Stuppin to in-license and develop drugs primarily to treat neurological conditions; the company was dissolved in 2009 after the failure of its drug candidate ancrod in a Phase III trial for ischemic stroke.
Mark Anthony Febbraio is a physiologist, academic and researcher. He is a professor and head of the Cellular and Molecular Metabolism Laboratory at the Monash Institute of Pharmaceutical Sciences (MIPS) of Monash University and a Senior Principal Research Fellow of the National Health and Medical Research Council (NHMRC).
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
